Avicanna Inc (AVCN) - Total Liabilities

Latest as of December 2025: CA$9.86 Million CAD ≈ $7.13 Million USD

Based on the latest financial reports, Avicanna Inc (AVCN) has total liabilities worth CA$9.86 Million CAD (≈ $7.13 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Avicanna Inc cash flow conversion to assess how effectively this company generates cash.

Avicanna Inc - Total Liabilities Trend (2016–2025)

This chart illustrates how Avicanna Inc's total liabilities have evolved over time, based on quarterly financial data. Check AVCN cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Avicanna Inc Competitors by Total Liabilities

The table below lists competitors of Avicanna Inc ranked by their total liabilities.

Company Country Total Liabilities
PT Mitra Pack Tbk
JK:PTMP
Indonesia Rp104.19 Billion
Berkah Beton Sadaya Tbk PT
JK:BEBS
Indonesia Rp88.66 Billion
Decade Resources Ltd
V:DEC
Canada CA$569.83K
Income Asset Management Group Ltd
AU:IAM
Australia AU$7.68 Million
Trust Stamp Inc
NASDAQ:IDAI
USA $4.97 Million
Thanasiri Group Public Company Limited
BK:THANA
Thailand ฿579.66 Million
Trematon Capital Investments
JSE:TMT
South Africa ZAC367.68 Million
Euro Manganese Inc
AU:EMN
Australia AU$34.27 Million

Liability Composition Analysis (2016–2025)

This chart breaks down Avicanna Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Avicanna Inc worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.86 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 3.47 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.46 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Avicanna Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Avicanna Inc (2016–2025)

The table below shows the annual total liabilities of Avicanna Inc from 2016 to 2025.

Year Total Liabilities Change
2025-12-31 CA$9.86 Million
≈ $7.13 Million
-5.00%
2024-12-31 CA$10.38 Million
≈ $7.51 Million
-25.89%
2023-12-31 CA$14.00 Million
≈ $10.13 Million
-1.14%
2022-12-31 CA$14.16 Million
≈ $10.24 Million
-8.01%
2021-12-31 CA$15.39 Million
≈ $11.14 Million
-5.25%
2020-12-31 CA$16.25 Million
≈ $11.75 Million
+6.26%
2019-12-31 CA$15.29 Million
≈ $11.06 Million
+748.74%
2018-12-31 CA$1.80 Million
≈ $1.30 Million
+41.13%
2017-12-31 CA$1.28 Million
≈ $923.33K
+939.73%
2016-12-31 CA$122.76K
≈ $88.80K
--

About Avicanna Inc

TO:AVCN Canada Drug Manufacturers - Specialty & Generic
Market Cap
$13.17 Million
CA$18.21 Million CAD
Market Cap Rank
#26195 Global
#1072 in Canada
Share Price
CA$0.15
Change (1 day)
+0.00%
52-Week Range
CA$0.15 - CA$0.30
All Time High
CA$6.90
About

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with vari… Read more